GSK’s multiple myeloma therapy Blenrep has taken a step closer to a remarkable comeback, with new Phase III data confirming that the antibody-drug conjugate (ADC) significantly extended overall survival (OS) in relapsed/refractory multiple myeloma patients compared with standard-of-care.
The topline result from the DREAMM-7 study unveiled on 14 November showed that Blenrep (belantamab mafodotin) in combination with bortezomib...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?